Findings

What does this study add?

• Plasma concentrations peaked 2 hours post-dose following repeated 200 mg and 400 mg doses of lasmiditan, with no accumulation from daily dosing due to its 4hr half-life.
• Daily administration of lasmiditan 200 mg for 7 days had no clinically relevant effects on the PK of caffeine, midazolam or tolbutamide.
• In both cohorts, the most common treatment-emergent adverse advent (TEAE) was dizziness, and for subjects receiving lasmiditan, most TEAEs occurred on Day 1.
• There was no increase in adverse events (AEs) upon administration of lasmiditan with PDC on Day 7.
• No clinically significant changes in clinical laboratory values, vital signs and electrocardiograms were reported.